Domov › Non-Hodgkinov lymfóm › Massachusetts › Boston
Klinické štúdie Non-Hodgkinov lymfóm v meste Boston, MA
26 štúdií pre Non-Hodgkinov lymfóm hľadá účastníkov v zariadeniach v meste Boston a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Prebieha náborFáza 1/2
- Dana Farber Cancer Institute, Boston
Epco, Zanu, Ritux for R/R FL or MZL
Prebieha náborFáza 2
- Dana-Farber Cancer Institute, Boston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Prebieha náborFáza 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Prebieha náborFáza 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Prebieha náborFáza 1/2
- Research Site, Boston
- Research Site, Boston
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Prebieha náborFáza 1/2
- Dana-Farber Cancer Institute, Boston
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Prebieha náborFáza 2
- Boston Medical Center, Boston
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Prebieha náborFáza 2
- Dana-Farber Cancer Institute, Boston
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Prebieha náborFáza 1
- Tufts Medical Center, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Prebieha náborFáza 1/2
- Dana-Farber Cancer Institute, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Prebieha náborFáza 1/2
- Massachusetts General Hospital, Boston
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Prebieha náborObservačná štúdia
- Dana Farber Cancer Institute, Boston
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Prebieha náborFáza 1Vítaní zdravých dobrovoľníkov
- Brigham and Women's Hospital, Boston
DALY II USA/ MB-CART2019.1 for DLBCL
Prebieha náborFáza 2
- Dana Farber Cancer Institute, Boston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Prebieha náborObservačná štúdia
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Prebieha náborFáza 1
- Dana Farber Cancer Institute, Boston
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
Prebieha náborObservačná štúdia
- Dana-Farber Cancer Institute, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Prebieha náborFáza 1/2
- Dana Farber Cancer Institute, Boston
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
Prebieha nábor
- Dana Farber Cancer Institute, Boston
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Prebieha náborFáza 1
- Massachusetts General Hospital, Boston
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Prebieha náborFáza 2
- Beth Israel Deaconess Medical Center, Boston
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Prebieha náborFáza 2Vítaní zdravých dobrovoľníkov
- DFCI/BWH Brigham and Women's Hospital, Boston
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Prebieha náborFáza 4
- Dana-Farber Cancer Institute, Boston
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Prebieha náborFáza 4
- Dana-Farber Cancer Institute, Boston
Study of SGR-1505 in Mature B-Cell Neoplasms
Prebieha náborFáza 1
- Beth Israel Deaconess Medical Center, Boston
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Prebieha náborFáza 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Štúdie Non-Hodgkinov lymfóm v iných mestách
- New York City, NY31 štúdií
- Houston, TX31 štúdií
- Nashville, TN21 štúdií
- Philadelphia, PA20 štúdií
- Baldwin Park, CA19 štúdií
- Washington, DC18 štúdií
- Chicago, IL18 štúdií
- Atlanta, GA18 štúdií
- Milwaukee, WI18 štúdií
- Columbus, OH18 štúdií
- Dallas, TX17 štúdií
- Seattle, WA16 štúdií
Iné štúdie v Boston
- Rakovina prsníka112 štúdií
- Nemalobunkový karcinóm pľúc90 štúdií
- Rakovina (všetky typy)85 štúdií
- Metastatická rakovina63 štúdií
- Kolorektálny karcinóm63 štúdií
- Rakovina pľúc62 štúdií
- Rakovina vaječníkov61 štúdií
- Rakovina prostaty59 štúdií
- Depresia52 štúdií
- Rakovina endometria50 štúdií
- Srdcové zlyhanie44 štúdií
- Akútna myeloidná leukémia44 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.